Immunomodulatory effect of macrolides: At what cost?
Maria Kipourou, Katerina Manika, Apostolos Papavasileiou and 4 more
Respiratory Medicine Case Reports · 2016
doi:10.1016/j.rmcr.2016.01.004 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
We present the case of a 60-year old female patient, with a 10 year history of non-CF bronchiectasis and use of macrolides as maintenance immunomodulatory treatment, who was diagnosed with macrolide-resistant Mycobacterium avium complex lung disease. Macrolides' immunomodulatory effect is appealing for non- CF bronchiectasis patients, hiding a high risk for resistance emergence.
Abstract licence: CC BY-NC
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.